PBIO OTC – Pressure BioSciences Update – Forecast

SOUTH EASTON, MA / ACCESSWIRE / June 1, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or the “Company”), a global leader in the development and sale of broadly enabling, high-pressure-based equipment, consumables, and specialty testing services to the worldwide biotherapeutics, nutraceuticals, cosmeceuticals, food and beverage, and other industries today highlighted the six key goals they expect to achieve during the month of June 2023, and discussed the significant financial impact expected to result for the Company in FY 2023 and beyond. The top six goals expected to be completed in June include:

1. Addition of Three $1M+ (Annual) Nano-CBD Commercial Distribution Contracts

• Leading Retailer (CBD Supply MD) recently introduced NanoBloom CBD to their multi-state client base.
• PBI believes the Agreement with CBD Supply MD will be worth $1.5M+ over the next 12 months.
• PBI anticipates three additional CBD retailers with similar revenue potential to close during June 2023.

2. Sale of Two Licenses ($1M+) for PBI’s Patented UltraShear™ Platform for Nano-THC Processing

• Multiple groups are negotiating a possible purchase of a 3-year exclusive THC processing license for a state.
• PBI anticipates the sale of two exclusive licenses to close during June 2023.
• PBI expects most license sales to generate – on average – about $1M in up-front fees.

3. Completion of Third (and Largest) Consumer Focus Group on Nano-THC

• Two focus groups have validated the market transforming speed and dosing efficiency of PBI’s Nano-THC.
• Third focus group expected to further validate these results, plus super-fast pain relief from topical use.

4. John Westlake, Canopy CBD Farms (“CCF”), to Launch as Master Distributor of Nano-Cannabis Products

• Assumes heightened role as a master distributor of PBIO nano-cannabis products in June 2023.
• John/CCF delivers multiple sales channels, a deep nationwide industry network, and access to media and capital.

5. Initial Production Runs in PBIO’s New Strategic Manufacturing Facilities

• PBI’s severe capacity limitations in current production facilities become relieved with new expansion transition into strategic partner Artisan Industries facilities, only 6 miles from PBI headquarters.

6. Dr. Denese Skin Science Collaboration Completes First Retinol Product R&D Phase – Expects Marketing LOI

• Retinol-based anti-aging creams and serums are among the Dr. Denese Skin Science top sellers on QVC.
• Dr. Denese believes PBIO’s UltraShear nanoemulsification technology is the enabling platform for a revolutionary new generation of skincare.
• PBI has completed the development of UltraShear-processed retinol with lipid-soluble Vitamin C formulations.
• PBI anticipates a formal product marketing Letter-of-Intent (LOI) on these products with Dr. Denese in June.

Mr. Richard T. Schumacher, PBIO’s President and CEO stated: “We have been laser-focused on making measurable progress on those areas that offer the best potential for rapid recurring revenue growth in the near future. I am pleased to say that the PBI Team has been highly successful in these endeavors. Progress on the six goals delineated here is a testament to their hard work and effectiveness – and to the value proposition of our UltraShear platform. All told, the incremental annual revenue expected from these goals, which our team expects to complete in June, should exceed several millions of dollars during the second half of FY 2023 alone, with incremental revenues growing further in FY 2024 and beyond.”

Mr. Schumacher concluded: “We have accomplished a great deal in product development, technology demonstrations, and early commercial traction over the past year – and we believe that PBIO is highly undervalued at current market prices. We are continuing to help current and future investors understand the enormous potential of our many assets, especially our revolutionary (and diversely patented) Ultra Shear nanoemulsions technology platform.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB:PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilizeboth constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers

NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) — FMW Media’s business TV show, New to The Street, announces the signing of a 12-month contract for filming and broadcasting tailored interviews and commercials about Pressure BioSciences, Inc . (OTCQB: PBIO) ($PBIO).

New to The Street’s TV anchors will interview the management team at PBIO with each show airing on New to The Street’s televised syndicated outlets on Newsmax and Fox Business Network , sponsored program on Bloomberg TV , and website www.newtothestreet.com .

Pressure BioSciences, Inc. develops and sells innovative extreme pressure-based platform technology solutions for the global life sciences industry. The Company generates revenues from its patented platforms: Pressure Cycling Technology (“PCT™”), BaroFold™ Platform, and Ultra Shear Technology (“UltraShear™” or “UST™”).

With over 300 PCT installations worldwide, their Who’s Who of blue-chip customers spanning industry, academia and government are using PBIO products for vaccine developments, soil/plant biology applications, biotherapeutics, and diverse other life sciences applications. A wide array of scientific key opinion leaders underpins their credibility as their new UltraShear technology launches a new era of delivering oil-based nutrients and therapeutics, invisibly solubilized as nanoemulsions of oil in water.

The New to The Street’s social media team and television network partners will re-share media content, creating a platform to increase awareness about PBIO. All broadcasted shows will stream on the New to The Street website, www.newtothestreet.com . On a schedule, show previews and commercial ads will air on selected New to The Street syndicated and sponsored TV platforms. Digital ads will stream on New to The Street’s billboard platform throughout New York City.

Richard T. Schumacher, President/CEO of Pressure BioSciences, Inc., states, “I look forward to appearing on New to The Street, to share our Company’s business success stories with viewers. PBIO commercializes its patented technologies to create and deploy products that are uniquely transformative in their markets. We are particularly excited about our UltraShear platform, now poised for explosive growth as a game-changer to the basis of competition across multiple diverse major markets. During each show, the objective will be to inform viewers about the Company growth strategies, current/ future products, and expected opportunities.”

TV viewers will hear about more about PBIO’s patented technologies, from PCT using alternating cycles of hydrostatic pressures to control biomolecular interactions and facilitate unprecedented scientific outcomes, to BaroFold controlling the critical refolding of proteins into active configurations for biopharmaceuticals, to UltraShear’s breakthroughs in speed and completeness of payload delivery across pharmaceuticals, nutraceuticals, cosmeceuticals, food/beverages, agrochem and other markets. Their platforms are gaining worldwide recognition, with customers daily increasing usage of their products from biomarker discovery to biopharmaceutical production to revolutions in treatment, nutrition, health and beauty.

Vince Caruso, CEO / Producer of New to The Street, states, “I am excited in having PBIO on the show for a 12-part TV series. They have patents, products, and a dedicated team that I believe our viewers will enjoy learning more about. With recognized scientific peer-reviewed publications about the Company’s products, and worldwide sales, the Company is positioned for a strong growth trajectory. The PBIO storyline is compelling, and I’m excited for the New to The Street audience to learn more about the Company.”

New to The Street’s TV interviews with Pressure BioSciences, Inc.’s management, airing on Newsmax (syndicated), Fox Business Network (syndicated), and Bloomberg TV (sponsored) “To Be Announced.”

About Pressure BioSciences, Inc . (OTCQB: PBIO) ($PBIO):

Pressure BioSciences, Inc. (OTCQB: PBIO) ($PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. The Company’s products utilize both constant and alternating pressure. Its patented Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. PBIO recently expanded its market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. The Company also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Management’s commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers – https://www.pressurebiosciences.com/ .

About New to The Street:

Additional Focus Groups Corroborate UltraShear Nano-THC Produces Equal to Much Better THC Experiences, Even from Lower THC Dosing Levels; Also, Lightning-Fast Pain Relief from Topical Use.

SOUTH EASTON, MA / ACCESSWIRE / May 9, 2023 / Pressure BioSciences, Inc. (OTCQB:PBIO) (“PBIO” or “Company”) today announced results from additional consumer focus group testing of a THC Nanoemulsion Oral Spray designed for rapid, direct absorption through the cheeks. The THC Nanoemulsion Oral Spray was prepared using PBI’s revolutionary Ultra Shear Technology™ (UltraShear™) platform by PBI’s California-based partner companies, including Crème De Canna (CdC), a CA-licensed manufacturer and long-established provider of innovative, high-quality cannabis products.

Additional consumer focus group testing more than doubled the original cohort of participants and has strongly affirmed multiple pivotal results on the UltraShear processed Nano-THC Oral Spray being powerfully differentiated from traditional THC dosing alternatives:

1. Speedy onset of first effects (average well under ten minutes – many reports in first few minutes) versus typical THC edibles requiring 30-60 minutes.
2. Much faster progression to maximum effects (average well under 40 minutes – many reports in 30 minutes or less) versus typical THC edibles requiring 60-120 minutes.
3. Eliminates health issues associated with smoking or vaping.
4. Enormous efficiency improvement in dose payload delivery allows equal to much better/greater THC experience from dosing down to a small fraction of user’s normal dosing levels.
5. Stable, all plant formulation is sterile packaged with no added preservatives.
6. Multiple testers applied even a single spray to painful body areas and reported fast to instant transdermal pain relief.

Mr. John B. Hollister, PBIO’s Director of Sales and Marketing, discussed highlights from the studies: “Most testing participants used lower doses of UltraShear Nano-THC than their usual dose level for THC products – and the vast majority of volunteers reported the same, more, or much more effect from the lower dosing of Nano-THC versus their normal dosing choices. Multiple normally heavy users of THC and many other participants reported onset of effects from the Nano-THC Oral Spray very quickly, even at significantly lower THC concentrations than usually consumed.”

Mr. Hollister continued: “Following completion of the oral spray studies, we were also delighted by unplanned outcomes from multiple participants spraying the Nano-THC onto bodily pain locations (joint, arthritis, soreness, etc.) – and reporting very rapid, nearly instant relief from localized pain. All of these reported results are unsurprising to us, as scientific literature has long documented the greatly increased bioavailability of water-insoluble valuable constituents when dissolved into sufficiently small (under 100 nm) oil droplets. PBI’s UltraShear platform accomplishes this with unmatched uniformity, tunable droplet size control, lower cost of production, better ease-of-use, and long-term stability.”

Mr. Richard T. Schumacher, President and CEO of PBIO, concluded: “These extended study results have confirmed the potential for a market transformation in THC consumption with a new oral/transdermal dosing modality in between the existing smoke/vape and edible food/beverage bifurcation of this enormous market. We believe that the customer experience with UltraShear processed Nano-THC will be compelling to drive a tidal change in the market, with potential explosive adoption of UltraShear processed Nano-THC.”

Mr. Schumacher continued: “We are experiencing similar reactions and developments as we work with early partners across multiple other markets in nutraceuticals, cosmeceuticals, food/beverage, and more. 2023 is poised to be a watershed transformational year for PBI, as we capitalize for roll-out of the UltraShear platform and converge upon our announced NASDAQ or NYSE uplisting goal.”

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB:PBIO) is a global leader in providing innovative, broadly enabling, high pressure-based solutions for a range of industries, including biotechnology, pharmaceutical, nutraceutical, cosmeceutical, and agrochemical, as well as food and beverage manufacturing. Our products utilizeboth constant and alternating pressure. Our patented enabling technology platform, Pressure Cycling Technology (PCT), utilizes alternating cycles of pressure to control bio-molecular interactions (such as cell lysis and biomolecule extraction) safely and reproducibly. PCT-based products are beginning to be widely used for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterrorism applications. We have recently expanded our market opportunities with the acquisition of the BaroFold™ patented technology platform, allowing us to enter the bio-pharma contract services and GMP manufacturing equipment sector. We have also developed the scalable and high-efficiency pressure-based UltraShear Technology™ (UltraShear™) platform, which allows for the creation of stable nanoemulsions of otherwise immiscible fluids. It also allows for the preparation of higher quality, homogenized, extended shelf-life or room temperature-stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. Our commitment to innovation and cutting-edge technology has established PBIO as a leader in the high-pressure industry, providing unique and effective solutions to our customers.